ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2538

Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis

Min Chen1, Xiao-Feng Li2, Chong Gao3 and Cai-Hong Wang4, 1The Second Hospital of Shanxi Medical Univerity, Taiyuan City, China, 2Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, 3Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 4The Second Hospital of Shanxi Medical Univerity, Taiyuan, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and treatment, T-Regulatory Cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints.We found that there was an imbalance between Th17 and Treg cells in the patients with active refractory RA, reduced absolute number of Treg cells was found in these patients.To observe the medium-term curative effect of rapamycin in the treatment of 25 cases newly diagnosed rheumatoid arthritis.

Methods:

Collecting 25 patients of newly diagnosed rheumatiod arthritis, which accorded with RA diagnosis standard of ACR in 1987. The patients were treated with rapamycin at a dose of 0.5mg every 2 days for 24 weeks,then we observed the change of clinical improvement and
immunological assessments after 24 weeks.

Results:

There was 25 patients were enrolled .After rapamycin treatment for 24 weeks,the mean DAS28 of them was decreased from 5.36[1.42] to 3.45[1.29](P=0.001). The absolute number of TregCD4+CD25+Foxp3+ cells significantly higher than baseline (30.24[14.44],46.64[27.54],P=0.025).The absolute number of Th17 cells was not significantly different (6.40[4.46],7.03[5.60],P>0.05),and the same as the ratio of Th17/Treg cells (0.25[0.18],0.19[0.16]),P>0.05). Meanwhile, the mean dose of prednisone was decrased form 11.25mg/d to 9.6mg/d.

Conclusion:

Rapamycin could induce the balance of Th17 cells and Treg cells,especially up-regulate the absolute number of Treg cells,thus induce remission in patients with newly diagnosed RA.


Disclosure: M. Chen, None; X. F. Li, None; C. Gao, None; C. H. Wang, None.

To cite this abstract in AMA style:

Chen M, Li XF, Gao C, Wang CH. Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/rapamycin-induces-remission-in-patients-with-newly-diagnosed-rheumatoid-arthritis/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rapamycin-induces-remission-in-patients-with-newly-diagnosed-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences